SBC Medical Group Holdings Inc

SBC Medical Group Holdings Inc. notified Nasdaq of non-compliance with independent director and audit committee requirements following a director's departure. Nasdaq has provided a cure period until July 9, 2027, or earlier, for the company to regain compliance by appointing a new independent director. Additionally, stockholders approved amendments to the company's certificate of incorporation, and the Board adopted amended bylaws, primarily to update corporate governance provisions related to director elections, removal, and other technical changes.

SBC Medical Group Holdings Inc. announced the opening of SBC MEN'S FLASH CLINIC Ikebukuro in Tokyo on August 6, 2026. This clinic is positioned as Japan's first specialized men's beard hair removal clinic, targeting the rapidly growing male aesthetic healthcare market. The new facility will operate with a highly standardized, capital-efficient model, aiming to optimize resource allocation, improve unit economics, and serve as an entry point for broader aesthetic services within SBC Medical's network. It also integrates AI-native management for operational efficiency.

SBC Medical Group Holdings Inc. announced its 2026 annual meeting of stockholders will be held virtually on July 9, 2026, Japan Standard Time (July 8, 2026, Eastern Time). Stockholders of record as of May 20, 2026, are invited to vote on several key proposals. These include the election of four directors, the ratification of MaloneBailey, LLP as the independent registered public accounting firm for fiscal year 2026, and multiple amendments to the company's Certificate of Incorporation.

SBC Medical Group Holdings Inc. announced its participation in five upcoming investor conferences scheduled for May and June 2026. The company plans to deliver webcast presentations and hold one-on-one meetings with institutional investors at these events. This engagement aims to enhance investor visibility and communicate its business as a Medical Services Organization, which was listed on Nasdaq in September 2024 and included in the Russell 3000® Index in June 2025.

SBC Medical Group Holdings Incorporated announced the inauguration of a new aesthetic dermatology section at BLEZ CLINIC in Bangkok, Thailand, in partnership with BLEZ ASIA Co., Ltd. The section, set to launch services in June 2026, marks SBC Medical's strategic entry into the rapidly growing Thai aesthetic healthcare market. This collaboration aims to deliver high-quality, Japanese-standard aesthetic services, initially targeting Japanese expatriates before expanding to the broader Thai and ASEAN markets.

SBC Medical Group Holdings announced that independent director Mike Sayama will not seek re-election at the upcoming 2026 Annual Meeting of Stockholders. His departure is not due to any disagreements with the company. Following this, the board will temporarily reduce its size to four members. The company plans to search for and appoint a new fifth independent director after the AGM, intending to restore the board to five members and fill key committee positions.

SBC Medical Group Holdings Inc. reported a significant decline in its first quarter 2026 financial results, with net income attributable to the company falling 47.4% year-over-year to $11.31 million. Basic and diluted earnings per share also decreased by 47.6% to $0.11. Total revenues, net, were down 9.0% to $43.06 million, and gross profit saw a 19.6% reduction compared to the same period in 2025.

SBC Medical Group Holdings Inc. reported its first-quarter 2026 financial results, with total revenues decreasing 9% year-over-year to $43 million. Net income attributable to the company fell 47% to $11 million, resulting in diluted EPS of $0.11, a 48% decline. The company attributed the revenue decrease primarily to a strategic structural reform involving a revision of the franchise fee structure in April 2025, noting solid core business performance otherwise.

SBC Medical Group Holdings Inc. announced it will release its first quarter ended March 31, 2026, financial results before the U.S. market opens on May 14, 2026. Following the release, management will host an earnings conference call at 8:30 a.m. Eastern Time, which will include a Q&A session for analysts and investors. Details for registration and access to materials are provided.

SBC Medical Group Holdings Inc. filed a 10-K/A to amend its 2025 10-K, primarily to include previously omitted information from Part III, Items 10-14, and update Part IV, Item 15. The amendment provides detailed corporate governance information, including board composition and committee responsibilities, and discloses executive compensation for 2024 and 2025. Key compensation figures include CEO Yoshiyuki Aikawa's 2025 salary of $12,000,000.